Barclays’s TherapeuticsMD TXMD Stock Holding History

Barclays’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-240	Closed	-$86K	–	6939
2017 Q1	$86K	Buy	+240	New	+$74.3K	﹤0.01%	4998

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays's TXMD Position: Q4 2025 in Review

Barclays sold out of TherapeuticsMD (TXMD) in Q4 2025, closing a stake of 44 shares — an estimated $47 sold.

Barclays first reported a position in TXMD in Q2 2013 and held it in 35 quarters. The position peaked at $698K in Q4 2015. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2025.

Barclays reported no remaining TherapeuticsMD position as of Q4 2025 after selling out during the quarter.
Barclays sold 44 TherapeuticsMD shares in Q4 2025, an estimated $47.
Barclays first reported a position in TherapeuticsMD in Q2 2013 and held it in 35 quarters.
Barclays's TherapeuticsMD position peaked at $698K in Q4 2015.
44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.